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A prospective study of lung disease 
in a cohort of early rheumatoid 
arthritis patients
A. Robles‑pérez1, p. Luburich2, S. Bolivar2, J. Dorca1, J. M. nolla3, M. Molina‑Molina1,4* & 
J. narváez3,4
Lung disease is common in patients with rheumatoid arthritis (RA). the onset of lung involvement 
in RA is not well known. the objective is to describe the features and evolution of lung involvement 
in early RA, its relationship with disease activity parameters, smoking and treatments. consecutive 
patients with early RA without respiratory symptoms were included and tracked for 5 years. Lung 
assessment included clinical, radiological and pulmonary function tests at diagnosis and during 
follow‑up. peripheral blood parameters (erythrocyte sedimentation rate, c reactive protein, 
rheumatoid factor and anti‑citrullinated peptide autoantibodies) and scales of articular involvement, 
such as DAS28-CRP, were evaluated. 40 patients were included and 32 completed the 5-year follow up. 
13 patients presented lung involvement in the initial 5 years after RA diagnosis, 3 of them interstitial 
lung disease. Significant decrease of diffusion lung transfer capacity of carbon monoxide over time 
was observed in six patients, 2 of them developed interstitial lung disease. DLCO decrease was 
correlated with higher values of CRP and ESR at diagnosis. Methotrexate was not associated with 
DLco deterioration or lung disease development. Subclinical progressive lung disease correlates with 
RA activity parameters. Smoking status and methotrexate were not associated with development or 
progression of lung disease.
Lung disease is commonly present in patients with rheumatoid arthritis (RA) and is a well-known cause of 
morbidity and  mortality1,2. In some cases, lung disease is present at diagnosis of the rheumatic manifestations, 
occasionally preceding the joint  symptoms3,4. However, the confirmation of lung disease is usually diagnosed 
after several months of presenting respiratory symptoms. The onset of lung impairment and its association with 
rheumatic disease or potential drug toxicity remains controversial since the majority of cases are identified 
months or years after RA diagnosis and treatment initiation. Therefore, it remains unknown if most interstitial 
lung disease (ILD)-RA cases present established fibrotic signs at diagnosis. Previous work has suggested an 
association between lung disease development and RA activity and  inflammation4–8. Therefore, the identifica-
tion of predictive factors of pulmonary involvement could help in optimizing lung screening for RA patients.
Treatments used for RA have been associated with both improvement and progression of lung disease. Data 
about the potential effect of methotrexate inducing pulmonary fibrosis are especially controversial, probably 
due to variability in methodology and difficulties in evaluating the lung state of these patients before initiating 
any RA  treatment9,10. Furthermore, lung evaluation through pulmonary functional test including assessment of 
diffusing lung capacity for carbon monoxide (DLCO) and high-resolution computed tomography (HRCT) is not 
a common procedure in the initial evaluation of all RA patients. Therefore, to elucidate whether lung disease is 
induced by these treatments or associated to the RA itself remains a challenge.
The objectives of this work are: to describe the features of lung involvement during the first 5 years from RA 
diagnosis; to investigate the relationship between systemic disease activity parameters, treatments used for RA 
and smoking with the presence of lung abnormalities.
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Materials and methods
patient recruitment. In 2012, newly RA diagnosed patients at the outpatient clinic of the Rheumatology 
Department, University Hospital of Bellvitge, were included and followed-up for 5 years. The inclusion criteria 
were as follows: (1) age > 18 years; (2) diagnosis of RA according to the 1987 American College of Rheuma-
tology classification  criteria11; (3) duration of joint symptoms > 6 weeks and < 24 months; (4) previous treat-
ment with nonsteroidal anti-inflammatory drugs, low dose of glucocorticosteroids (≤ 7.5 mg/day of prednisone 
or equivalent) or disease-modifying antirheumatic drugs (i.e., methotrexate or leflunomide) for no more than 
3 months; and (5) absence of respiratory symptoms (patients were asked about dyspnea, using the modified 
Medical Research Council scale (mMRC), cough or wheezing). Subjects were excluded if they had other collagen 
vascular disorders, chronic respiratory or heart diseases prior to the RA diagnosis.
ethics approval. The study was conducted in accordance with the principles of the Declaration of Helsinki 
and the International Conference for Harmonization. Informed consent was obtained for every patient and the 
study was approved by the Clinical Research Ethics Committee of Bellvitge University Hospital.
clinical assessment. Clinical and epidemiological data were collected at RA diagnosis for inclusion. This 
included age, gender, duration of joint symptoms, smoking habits, the acute phase reactants erythrocyte sedi-
mentation rate (ESR) and C-reactive protein (CRP), serological rheumatoid factor (RF) and anti-citrullinated 
peptyde autoantibodies (ACPA), swollen and tender joint count in 28 joints (DAS28-CRP score). ACPA levels 
(immunoglobulin G) were measured using a commercially available second-generation enzyme-linked immu-
nosorbent assay kit: EliATM CCP Assay on an ImmunoCAP250 instrument (Phadia, Germany). During the 
same time, baseline respiratory assessment (dyspnea, cough, chest auscultation), chest radiograph (CR) and 
pulmonary function tests (PFT) were performed. The PFT included forced spirometry, for analyzing forced vital 
capacity (FVC), forced expiratory volume in the first second (FEV1), and pletismography for evaluating DLCO. 
All tests were done and interpreted at the Respiratory Department in accordance with the Spanish Society of 
Respiratory Medicine and Thoracic Surgery  guidelines11.
During the follow-up, the same serological reactants and antibodies were collected and analyzed by a multi-
disciplinary team. The clinical, radiological and functional respiratory evaluation was repeated every year until 
the end of the study. In those patients with lung abnormalities in the CR, any abnormality in spirometry (defined 
as < 80% of FVC or FEV1 and/or DLCO), or significant decrease (> 10% on FVC and/or > 15% on DLCO) a 
high-resolution computed tomography (HRCT) of the chest was performed. The type of lung abnormality and 
the predominant radiological pattern on the HRCT were identified. HRCT features of ILD included ground glass 
opacities, septal thickening or reticulation, honeycombing, traction bronchiectasis and pulmonary nodules. The 
HRCT patterns were identified as usual interstitial pneumonia (UIP), including consistent UIP, probable UIP 
and indeterminate UIP, and non-UIP, including radiological features of non-specific interstitial pneumonia 
(NSIP) and other less frequently present patterns. Every HRCT was independently reviewed by two expert lung 
disease radiologists.
Information about treatment received for the rheumatologic disease and for the respiratory involvement 
(when applicable), was also collected during the follow up period.
Statistical analysis. Categorical data are described as number of cases and percentage. Continuous vari-
ables are described as number of cases, mean, standard deviation (SD), median and interquartile range (Q1–Q3). 
The comparison between variables over time was performed with the t-test or Kruskal–Wallis test where appli-
cable. For both FVC and DLCO a covariance analysis was performed to describe the evolution over time. This 
model was adjusted with other variables, such as ESR, CRP, ACPA, RF, DAS28-CRP, age, sex, smoking status 
and treatment for RA. Data were analyzed with R software 3.4.0 (https ://cran.r-proje ct.org/bin/windo ws/base/
old/3.4.0/). p values of < 0.05 are considered statistically significant.
Results
characteristics of the cohort. Forty patients (30 women) were recruited and followed-up. Mean age (SD) 
at inclusion was 47.1 (13.4) years. After 5 years, six patients had to discontinue the study because of a housing 
change, and two patients neglected to attend the last visits. Patient characteristics at inclusion and after 5 years 
are summarized in Table 1. Two patients presented ILD with preserved FVC at the initial lung evaluation: one 
NSIP and one organizing pneumonia (OP).
During the 5 years of follow up patients received different treatments for the rheumatologic condition: metho-
trexate, leflunomide, prednisone and biologic treatments such as infliximab, rituximab, certolizumab, abatacept 
and tocilizumab. The number of patients and duration of treatment is shown in Table 2. The most frequent 
treatment was methotrexate (71.9%). Six patients discontinued treatment with methotrexate. The reasons varied: 
improvement of joint involvement (3 patients), gastrointestinal adverse events (2 patients) and new-onset ILD 
(1 patient). One patient started methotrexate for his joint involvement. Six patients discontinued treatment with 
leflunomide. The reasons stated: worsening of joint pain that required another therapeutic strategy (5 patients) 
and headache (1 patient). Nine patients initiated glucocorticosteroids and five began a biologic medication. 
Changes on treatment over time were made by a rheumatologist according to disease evolution. Smoking habit 
increased over time (4 new cases after 5 years).
Serological markers of RA activity ESR and CRP decreased after 5 years, while the mean value of RF increased. 
DAS28-CRP values were significantly lower after 5 years (Table 1). No significant correlation was observed 
between changes in these values and the different treatments used for the rheumatologic disease. No hospitaliza-
tion was required, and no patient died during the 5 years of follow up.
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features of pulmonary involvement. At the beginning of the study no patient presented respiratory 
symptoms, but ILD with preserved FVC was identified in two of them (5%) and diffuse cylindrical bronchiec-
tasis in the absence of fibrosis in 7 of them (17.5%). In these cases the suspicion of lung disease was due to low 
DLCO values on PFT.
No significant differences in the mean PFT values, FVC or DLCO, at inclusion and after 5 years were observed 
in the overall cohort (Table 1). During the study, six patients (18.8%) showed a significant decrease of DLCO and 
underwent HRCT. Four of them (12.5%) presented radiologic abnormalities on the HRCT. Five of these patients 
(15.6%) presented mild exertional dyspnea (mMRC stage I). No other respiratory symptoms were observed.
Overall, the rate of lung involvement in our cohort at the first 5 years of RA diagnosis was 32.5%, from 
which 7.5% was ILD. Emphysema and diffuse cylindrical bronchiectasis in the absence of fibrosis were the most 
frequently identified abnormalities in the HRCT. One patient presented new onset of ILD after 5 years of RA 
diagnosis, with the HRCT pattern of UIP (see Supplementary Data).
The patient with NSIP at the beginning of the study discontinued follow-up and the patient with OP pre-
sented clinical and functional progression despite corticosteroid treatment. The seven patients presenting diffuse 
cylindrical bronchiectasis at baseline did not show radiologic progression or associated respiratory symptoms, 
such as increased volume of sputum or respiratory infections over 5 years. The main radiologic findings are 
summarized in Table 3.
pulmonary involvement and risk factors. Smoking history was only present in 3 patients with pulmo-
nary involvement and did not associate a worsening in pulmonary function parameters. Baseline values of ESR 
and CRP and change of ACPA value over time showed an inverse significant correlation with DLCO decrease. 
No correlation between FVC change and other variables was observed. The results were adjusted for smoking 
Table 1.  Patient features at inclusion and after 5 years. Results are expressed as mean (SD) or median (Q1–Q3) 
where applicable. FVC forced vital capacity, DLCO diffusion lung transfer of carbon monoxide, RF rheumatoid 
factor, ACPA anti-citrullinated peptide autoantibodies, CRP C reactive protein, ESR erythrocyte sedimentation 
rate. The values of p < 0.05 are considered statistically significant.
2012 2017 p
Ever smoker, n (%) 15 (41.7) 19 (59.4) –
FVC% 106 (15.8) 110 (19.7) 0.437
DLCO% 85.2 (20.3) 78.2 (17.5) 0.122
RF, IU/mL 25.6 (12.6–60.4) 66.0 (15.9–224) 0.201
ACPA, U/mL 116 (10.8–604) 115 (1–428) 0.710
CRP, mg/L 6.55 (2.92–15.7) 2.70 (0.75–6.47) 0.005
ESR, mm/h 26 (16–37.2) 19 (7.25–30) 0.080
DAS28-CRP 5.24 (4.48–6.05) 2.25 (1.96–3.38)  < 0.001
Table 2.  Treatment used for rheumatoid arthritis in our cohort. Results are expressed as mean (SD) or median 
(Q1–Q3) were applicable.
2012, n (%) 2017, n (%) Duration of treatment, months
Methotrexate 27 (67.5) 23 (71.9) 57.5 (7.1)
Leflunomide 10 (25) 7 (21.9) 50.7 (16.7)
Prednisone 4 (10) 13 (40) 50.8 (16.4)
Biologic treatment 0 (0) 5 (15.6) 24 (6–48)
Table 3.  Radiologic findings in patients who underwent HRCT scan at follow up. HRCT high resolution 
computed tomography.
Patients with DLCO decrease HRCT findings
Patient 1 Emphysema, cylindrical bronchiectasis
Patient 2 Emphysema, usual interstitial pneumonia
Patient 3 No radiological findings
Patient 4 Cylindrical bronchiectasis
Patient 5 Emphysema, cylindrical bronchiectasis, organizing pneumonia
Patient 6 No radiological abnormalities
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status, baseline FVC and DLCO values. Methotrexate was not associated with ILD development or progression. 
Contrary, a direct correlation between DLCO stability and methotrexate treatment was observed, even after 
adjusting for RA activity biomarkers. FVC and DLCO correlations are shown in Tables 4 and 5 respectively.
Discussion
In this single-center prospective cohort study of patients with early RA, we demonstrate that the systematic lung 
evaluation, including HRCT and DLCO, allows the identification of respiratory abnormalities in more than one-
third of cases, most of them without symptoms. On the other hand, disease activity measured through scales and 
serum acute phase markers decreased after 5 years of follow up in most cases. This can be attributed to a better 
control of the inflammatory process associated to the treatment, as previously  reported13.
No changes in mean lung function in the overall sample were observed. However, 6 patients (18.8%) pre-
sented a significant decrease in DLCO values, four of them with airway or parenchymal abnormalities on the 
HRCT. The variability in the reported prevalence of RA lung involvement could be due to the different protocols 
 used4,5,7,24–26. If simple spirometry is used, these patients cannot be identified. In our work those patients with 
lung disease presented higher rates of inflammatory serological markers, such as ESR and CRP, in line with pre-
vious  studies14–17. In our study, higher values of CRP and ESR at RA diagnosis associated a DLCO decrease over 
time. The presence of inflammatory proteins in the lungs has been associated with progressive lung  disease16 and 
higher rates of ESR associate ground glass opacities on lung HRCT 15. Sparks et al. reported a higher risk for the 
development of RA-ILD in patients with higher values of DAS28 in a prospective cohort of RA  patients8. This 
association between local and systemic inflammation with lung disease suggested that a better control of the 
systemic rheumatoid process could associate a lower risk of developing progressive lung involvement. However, 
our data show that some RA patients present lung disorders over time despite an improvement in join symptoms 
or inflammatory markers. So, other factors associated with the RA could contribute to the lung involvement.
Furthermore, patients that present ILD several years after onset of RA and receive methotrexate are difficult 
to distinguish as RA-ILD or ILD induced by the drug because they usually lack an initial lung evaluation. The 
Table 4.  Correlation between FVC evolution and different variables. The values of p < 0.05 are considered 
statistically significant. RF rheumatoid factor, ACPA anti-citrullinated peptide autoantibodies, CRP C reactive 
protein, ESR erythrocyte sedimentation rate.
B CI p
Age − 0.20 − 057 to 0.16 0.253
Gender (male) 0.05 − 9.42 to 9.51 0.992
Ever smoker 5.84 − 0.01 to 0.04 0.193
RF 0.02 − 0.02 to 0.03 0.709
ACPA 0.00 0.00 to 0.01 0.816
CRP 0.06 − 0.10 to 0.22 0.418
ESR 0.23 − 0.02 to 0.48 0.067
DAS28-CRP 2.88 − 1.35 to 7.11 0.166
Methotrexate − 1.87 − 11.70 to 7.97 0.690
Leflunomide 1.87 − 7.97 to 11.70 0.690
Prednisone 6.76 − 5.07 to 18.60 0.241
Table 5.  Correlation between DLCO evolution and different variables. The values of p < 0.05 are considered 
statistically significant. RF rheumatoid factor, ACPA anti-citrullinated peptide autoantibodies, CRP C reactive 
protein, ESR erythrocyte sedimentation rate.
B CI p
Age − 0.04 − 0.04 to 0.33 0.842
Gender (male) 3.31 − 6.81 to 13.44 0.509
Ever smoker − 2.15 − 11.20 to 6.89 0.630
RF 0.01 − 0.02 to 0.03 0.709
ACPA at diagnosis 0.00 − 0.01 to 0.01 0.883
ACPA evolution − 0.01 − 0.01 to 0.00 0.005
CRP − 0.27 − 0.45 to − 0.10 0.003
ESR − 0.28 − 0.54 to − 0.03 0.028
DAS28-CRP − 3.20 − 8.16 to 1.77 0.199
Methotrexate 8.95 0.10 to 17.79 0.048
Leflunomide − 7.69 − 16.92 to 1.55 0.099
Prednisone − 2.36 − 17.17 to 12.45 0.747
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systematic lung functional evaluation from RA diagnosis showed that DLCO did not decrease in those patients 
treated with methotrexate. Only one patient stopped methotrexate because of lung involvement, but no clear 
toxicity was proven. Traditionally methotrexate had been related with lung toxicity, including new onset or 
worsening ILD, with toxicity rates up to 8%18. However, recent data advocate its safe use. Several meta-analysis 
of clinical trials have shown that treatment with methotrexate does not increase the risk of non-infectious lung 
disease as compared with other treatments for  RA19–21. Furthermore, methotrexate use in RA is associated with 
 survival22,23. The use of methotrexate in our study associated a good control of the rheumatic disease without 
higher risk for ILD. Nevertheless, performing HRCT scan and monitoring of lung function, especially in the 
first months of treatment would be recommended, as well as in other treatments for RA.
Our results suggest that lung disease may be identified at diagnosis and in the first years after RA diag-
nosis. Airway involvement is not uncommon in RA patients, especially in the form of bronchiectasis and/or 
 bronchiolitis7. In our cohort these patients presented clinical and functional stability after 5 years and did not 
associate an increased risk of mortality, which differs from previous  data27,28. However, respiratory infections 
could be more frequent in these cases after years and in the context of some biological treatments. Up to 6.3% of 
our cohort developed clinically significant ILD. Though radiological findings in the first years of RA are variable 
and non-specific as described in previous  studies4,5,7,24–26, ILD can develop in early  RA3. Clinically significant 
RA-ILD has been observed on average in 8 to 10% of patients with  RA3,29–31. Therefore, ILD may develop at any 
time of the rheumatologic disease and, when no systematic evaluation is performed from RA diagnosis, ILD can 
not be certainly attributed to the disease or the treatment. Finally, an optimized management and early treatment 
of RA-ILD could change this less than optimal progression.
The main limiting factor of our study is the total number of patients included, similar to previous works that 
include early RA patients, since recruiting patients with recent RA diagnosis before receiving methotrexate or 
other immunomodulators for improving join pain or activity limitation remain difficult. Future multi-center 
studies should be performed to validate our results. Despite this, the present study helps to clarify the natural 
history of the disease by showing that lung involvement in RA is present even from the beginning of the rheu-
matic process and could be related to the disease activity.
In conclusion, a systematic clinical and PFT evaluation of the lung (including DLCO) enables early identifi-
cation of RA-ILD and other types of lung involvement through HRCT. Patients at higher risk may be identified 
through serological markers of disease activity. Therefore, it could help optimize RA treatments and lung manage-
ment from initial stages, in the attempt to avert progression to advanced stages. Finally, the use of methotrexate 
has not been associated with a higher incidence of lung involvement.
Data availability
The datasets generated during and/or analysed during the current study are available from the corresponding 
author on reasonable request.
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